High incidence of non-B and recombinant HIV-1 strains in newly diagnosed patients in Galicia, Spain: Study of genotypic resistance

Antiviral Therapy

Volumn 8, Issue 4, 2003, Pages 355-360

  Pérez Alvarez, Lucía ^a   Carmona, Rocío ^a   Muñoz, Mercedes ^a   Delgado, Elena ^a   Thomson, Michael M ^a   Contreras, Gerardo ^a   Pedreira, José D ^b   Rodríguez Real, Rafael ^c   Vázquez de Parga, Elena ^a   Medrano, Leandro ^a   Taboada, José Antonio ^d   Nájera, Rafael ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

^c Complejo Hospitalario ^*  (Spain)

^d Xunta de Galicia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; AGED; ARTICLE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SPAIN; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ADULT; AGED; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MUTATION; RECOMBINATION, GENETIC; RNA, VIRAL; SPAIN;

EID: 10744223182     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Nájera R, Delgado E, Pérez-Alvarez L & Thomson MM. Genetic recombination and its role in the development of the HIV-1 pandemic. AIDS 2002; 16(Suppl. 4):S3-SI6.
2. Kuritzkes DR. Selected topics from the 8th Conference on Retroviruses & Opportunistic Infections. HIV Clinical Trials 2001; 2:219-226.
3. Little SJ, Holte S, Routy J-P, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS & Richmann DD. Antiretroviral-drug resistance among patients recently infected with HIV. New England Journal of Medicine 2002; 347:385-394.
4. Boden D, Hurlev A, Zhang L, Cao Y, Jones E, Tsay J, IP J, Farthing C, Limoli K, Parkin N & Markowitz M. HIV-1 drug resistance in newly infected individuals. Journal of the American Medical Association 1999; 282:1135-1141.
5. Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Cote P, LeBlanc R, Lefebvre E, Spira B, Tsoukas C, Sekaly RP, Conway B, Mayers D & Routy JP. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection study. AIDS 2000; 14:F17-F23.
6. Weinstock H, Respess R, Heneine W, Petropolous CJ, Hellman NS, Luo CC, Pau CP, Woods T, Gwinn M & Kaplan J. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998. Journal of Infectious Diseases 2000; 182:330-333.
7. Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, Parkin N, Boden D & Markowitz M. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002; 16:1511-1519.
8. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP & Kahn JO. Time trend in primary HIV-1 drug resistance among recent infected persons. Journal of the American Medical Association 2002; 288:181-188.
9. Yerly, S, Vora S, Rizzardi P, Chave JP, Vernazza PL, Flepp M, Telenti A, Battegay M, Veuthey AC, Bru JR, Rickenbach M, Hirschel B & Perrin L. Acute HIV infection: Impact on the spread of HIV and transmission of drug resistance. AIDS 2001; 15:2287-2292.
10. Balotta C, Berlusconi A, Pan A, Violin M, Riva C, Colombo MC, Gori A, Papagno L, Corvasce S, Mazzucchelli R, Facchi G, Velleca R, Saporetti G, Galli M, Rusconi S & Moroni M. Prevalence of transmitted nucleoside analogue-resistant HIV strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals. Antiviral Therapy 2000; 5:7-14.
11. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. British Medical Journal 2001; 322:1087-1088.
12. Fidler S, Frater J, Clarke J & Weber J. HIV drug resistance in primary infections in the UK. British Medical Journal 323:632.
13. Kindelan JM, Giménez-Domenech R, Vidal-Verdu E & Madueño J. Prevalence of primary mutations in human immunodeficiency virus with resistance to nucleoside analogues in naive human immunodeficiency virus-infected patients from Andalusia. Andalusian Group for the Study of Infectious diseases (GAEI). Medicina Clinica 2000; 115:423-425.
14. Duwe S, Brunn M, Altmann D, Hamouda O, Schmidt B, Walter H, Pauli G & Kucherer C. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German seroconverter study. Journal of Acquired Immune Deficiency Syndromes 2001; 26:266-273.
15. Vandamme A. HIV-1 drug resistance guidelines- European issues. 1st European HIV Drug Resistance Workshop, Luxembourg, 6-8 March 2003.
16. Pérez-Olmeda M, del Romero J, Rubio A, Ruiz L, Rodríguez C, Leal M, Clotet B & Soriano V. Primary HIV-1 drug resistance in Spain before and after the introduction of protease inhibitors. Journal of Medical Virology 2001; 63:85-87.
17. Re MC, Monari P, Borderi M, Tadolini M, Verucchi G, Vitone F, Borderi M & La Placa M. Presence of genotypic resistance to antiretroviral drugs in a cohort of therapy naive HIV-1 infected Italian patients. Journal of Acquired Immune Deficiency Syndromes 2001; 27:315-320.
18. De Mendoza C, del Romero J, Rodríguez C, Corral A & Soriano V. Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid. AIDS 2002; 16:1830-1832.
19. Villahermosa ML, Thomson MM, Vázquez de Parga E, Cuevas MT, Contreras G, Pérez-Alvarez L, Delgado E, Manjón N, Medrano L & Nájera R. Improved conditions for extraction and amplification of human immunodeficiency virus type 1 from plasma samples with low viral load. Journal of Human Virology 2000; 3:27-35.
20. Pérez-Alvarez L, Cuevas MT, Villahermosa ML, Pedreira JD, Manjón N, Herrero I, López-Calvo S, Delgado E, Vázquez de Parga E, Medrano L, Thomson MM, Taboada JA & Nájera, R. Prevalence of drug resistance mutations in B, non-B subtypes and recombinant forms of human immunodeficiency virus type 1 in infected individuals in Spain (Galicia). Jóurnal of Human Virology 2001; 4:35-38.
21. Thomson MM, Delgado E, Manjón N, Ocampo A, Villahermosa ML, Mariño A, Herrero I, Cuevas MT, Vázquez de Parga E, Pérez-Alvarez L, Medrano L, Taboada JA & Nájera R. HIV-1 genetic diversity in Galicia Spain: BG intersubtype recombinant viruses circulating among injecting drug users. AIDS 2001; 15:509-516.
22. Fleury H, Recordon-Pinson P, Caumont A, Faure M, Roques P, Plantier J-C, Couturier E, Dormont D, Masquelier B, Simon F & the Agence Nationale de Recherche sur le SIDA AC11 Laboratory Network. HIV type 1 diversity in France, 1999-2001: molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretroviral drugs. AIDS Research & Human Retroviruses 2003; 19:41-47.
23. Op de Coul EL, Coutinho RA, van der Schoot A, van Doornum GJ, Lukashov VV, Goudsmit J & Cornelissen M; Dutch HIV-1 subtype surveillance. The impact of immigration on env HIV-1 subtype distribution among heterosexuals in the Netherlands: influx of subtype B and non-B strains. AIDS 2001; 15:2277-2286.
24. Barlow KL, Tatt ID, Cane PA, Pillay D & Clewley JP. Recombinant strains of HIV type 1 in the United Kingdom. AIDS Research & Human Retroviruses 2001; 17:467-474.
25. Boni J, Pyra H, Gebhardt M, Perrin L, Burgisser P, Matter L, Fierz W, Erb P, Piffaretti JC, Minder E, Grob P, Burckhardt JJ, Zwahlen M & Schupbach J. High frequency of non-B subtypes in newly diagnosed HIV-infections in Switzerland. Journal of Acquired Immune Deficiency Syndromes 1999; 22:174-179.
26. Esteves A, Parreira R, Veenno T, Franco M, Piedade J, Germano De Sousa J & Canas-Ferreira WF. Molecular epidemiology of HIV type 1 infection in Portugal: high prevalence of non-B subtypes. AIDS Research & Human Retroviruses 2002; 18:313-325.
27. Villahermosa ML, Pérez-Álvarez L, Cuevas MT, Vázquez de Parga E, Delgado E, Thomson MM, Medrano L, Cuevas L & Nájera R. Protease and RT sequences of B and non-B subtype HIV-1 viruses from Latin-America and Spain show distinct aminoacid mutation patterns in treated and drug-naive patients. 5th International Workshop on HIV Drug Resistance & Treatment Strategies, Arizona, USA, June 4-8, 2001.
28. Kantor R, Katzenstein D, Camacho R, Harrigan PR, Tanuri A, Pillay D, Vandamme A, Phanuphak P, Sugiura W, Soriano V, Morris L, Grossman Z, Brigido LF, Schapiro JM & Shafer SW. Genotypic analyses of RT and Protease sequences from persons infected with non-subtype B HIV-1. 10th Conference on Retroviruses & Opportunistic Infection. Boston, Mass., USA, February 10-14, 2003.
29. Pérez-Alvarez L, Thomson MM, Villahermosa ML, Vázquez de Parga E, Rodríguez A, Cuevas MT, Delgado E, Manjón N, Miralles C, Medrano L, Taboada JA, Nájeta R & the Spanish Group for Antiretroviral Resistance Studies in Galicia. HIV-1 subtype G and BG recombinant viruses in Spanish natives: evidence of characteristic mutations in reverse transcriptase and protease. AIDS 2001; 15:1907-1915.